Literature DB >> 28457019

Dynamics of von Willebrand factor reactivity in sickle cell disease during vaso-occlusive crisis and steady state.

J W R Sins1,2, M Schimmel1, B M Luken3, E Nur1, S S Zeerleder1,3, C F J van Tuijn1, D P M Brandjes4, W F Kopatz5, R T Urbanus6, J C M Meijers5,7, B J Biemond1, K Fijnvandraat2,7.   

Abstract

Essentials The role of von Willebrand Factor (VWF) in the pathophysiology of sickle cell disease is unclear. We assessed markers of VWF during admission for vaso-occlusive crisis (VOC) and steady state. VWF reactivity was higher during VOC and was associated with inflammation and neutrophil activation. Hyper-adhesive VWF may promote VOC in sickle cell disease.
SUMMARY: Background Endothelial activation plays a central role in the pathophysiology of vaso-occlusion in sickle cell disease (SCD), facilitating adhesive interactions with circulating blood cells. Upon activation, various adhesive molecules are expressed, including von Willebrand factor (VWF). Increased VWF levels have been observed in patients with SCD during steady state. However, the role of VWF in the pathogenesis of SCD vaso-occlusion is unclear. Objectives To longitudinally assess the quantity and reactivity of VWF and its regulating protease ADAMTS-13 during vaso-occlusive crisis (VOC). Methods In this observational study, we obtained sequential blood samples in adult SCD patients during VOC. Results VWF reactivity was significantly higher during VOC (active VWF, VWF glycoprotein Ib-binding activity, and high molecular weight multimers), whereas platelet count and levels of ADAMTS-13 antigen and ADAMTS-13 activity were concomitantly lower than during steady state. Levels of VWF antigen, VWF propeptide (VWF:pp) and ADAMTS-13 specific activity did not change during VOC. VWF reactivity correlated strongly with markers of inflammation and neutrophil activation, and was inversely correlated with the platelet count. In patients who developed acute chest syndrome, levels of VWF, VWF:pp and active, hyperadhesive VWF were significantly higher, whereas ADAMTS-13 activity was lower, than in patients without this complication. Conclusions We provide the first evidence that VOC in SCD is associated with increased reactivity of VWF, without a pronounced ADAMTS-13 deficiency. This hyper-reactivity may be explained by resistance of VWF to proteolysis, secondary to processes such as inflammation and oxidative stress. Hyperadhesive VWF, scavenging blood cells in the microcirculation, may thereby amplify and sustain VOC in SCD.
© 2017 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  cell adhesion; inflammation; sickle cell disease; vascular endothelium; von Willebrand factor

Mesh:

Substances:

Year:  2017        PMID: 28457019     DOI: 10.1111/jth.13728

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  7 in total

1.  Role of the coagulation system in the pathogenesis of sickle cell disease.

Authors:  Md Nasimuzzaman; Punam Malik
Journal:  Blood Adv       Date:  2019-10-22

2.  Endothelial VWF is critical for the pathogenesis of vaso-occlusive episode in a mouse model of sickle cell disease.

Authors:  Huiping Shi; Bojing Shao; Liang Gao; Thamizhiniyan Venkatesan; John Michael McDaniel; Meixiang Zhou; Samuel McGee; Pengchun Yu; Jasimuddin Ahamed; Janna Journeycake; James N George; Lijun Xia
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-15       Impact factor: 12.779

3.  Determination of von Willebrand factor level in patient with sickle cell diseasein vaso-occlusive crisis.

Authors:  Kingsley Akaba; Benedict Nwogoh; Olukayode Oshatuyi
Journal:  Res Pract Thromb Haemost       Date:  2020-07-10

4.  The aptamer BT200 effectively inhibits von Willebrand factor (VWF) dependent platelet function after stimulated VWF release by desmopressin or endotoxin.

Authors:  Katarina D Kovacevic; Nina Buchtele; Christian Schoergenhofer; Ulla Derhaschnig; Georg Gelbenegger; Christine Brostjan; Shuhao Zhu; James C Gilbert; Bernd Jilma
Journal:  Sci Rep       Date:  2020-07-07       Impact factor: 4.379

Review 5.  Emerging disease-modifying therapies for sickle cell disease.

Authors:  Marcus A Carden; Jane Little
Journal:  Haematologica       Date:  2019-08-14       Impact factor: 9.941

6.  ADAMTS13 and von Willebrand factor assessment in steady state and acute vaso-occlusive crisis of sickle cell disease.

Authors:  Julien Demagny; Aurélie Driss; Alain Stepanian; Nadia Anguel; Louis Affo; Damien Roux; Anoosha Habibi; Sandrine Benghezal; Sophie Capdenat; Paul Coppo; Françoise Driss; Agnès Veyradier
Journal:  Res Pract Thromb Haemost       Date:  2020-12-18

7.  Application of high-fat cell model in steady-state regulation of vascular function.

Authors:  Qinghong Song; Yan Zhang
Journal:  Saudi J Biol Sci       Date:  2019-09-24       Impact factor: 4.219

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.